Marrone Bio Innovations

Marrone Bio Innovations, Inc., a biopesticide company, engages in the discovery, development, and marketing of natural products for weed, pest, and plant disease management. Its products include Regalia, a product that protects food and ornamental crops from fungal and bacterial diseases; GreenMatch EX, a post-emergence herbicide for burndown weed control for organic growers; and GreenMatch, a burndown herbicide that controls various annual and perennial weeds. The company also offers insecticides, herbicides, and products for controlling invasive zebra and quagga mussels in waterways. In addition, it finds naturally occurring microorganisms from habitats and develops them into products for controlling insects, weeds, nematodes, and plant diseases. The company provides its products online. Marrone Bio Innovations, Inc. was founded in 2006 and is based in Davis, California.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pro Farm Group, Inc. engages in the provision of biological-based solutions for agricultural crops, turf protection, seed treatment, plant health and waterway systems. Its products include Grandevo Insecticide, Majestene Nematicide, Regalia Fungicide, Stargus Fungicide, Venerate Insecticide, Amplitude Fungicide, Regalia Rx Plant Health, Zelto Nematicide, Zequanox Molluscicide and Haven. The company was founded by Pamela G. Marrone on June 15, 2006 and is headquartered in Raleigh, NC.

American Resources Corp

IMARA

Comstock Mining

ObsEva

Synchronoss

Penny stocks can turn a quick profit. These 7 picks are designed to do so before the end of this year and cover multiple sectors.

7 Penny Stocks to Book Profits on Before 2022

Marrone Bio's (MBII) third-quarter revenues were driven by strategic focus on global expansion in the major row crops.

Marrone Bio (MBII) Q3 Earnings In Line, Revenues Lag Estimates

Marrone Bio Innovations' (MBII) CEO Kevin Helash on Q3 2021 Results - Earnings Call Transcript

Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of 0.00% and -8.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Marrone Bio Innovations, Inc. (MBII) Reports Q3 Loss, Misses Revenue Estimates

DAVIS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the third quarter ended September 30, 2021. Key results include:

Marrone Bio Innovations, Inc. Reports Third-Quarter 2021 Financial Results

DAVIS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (Nasdaq: MBII) today announced that it has received a letter from the Listing Qualifications Department of the Nasdaq Capital Market notifying the company of its noncompliance with Nasdaq Listing Rule 5550(a)(2) as a result of the company's closing bid price being below $1.00 per share for 30 consecutive days.

Marrone Bio Innovations Receives Nasdaq Notice Regarding Failure to Satisfy a Continued Listing Rule

Marrone Bio Innovations, Inc. (MBII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Marrone Bio Innovations, Inc. (MBII) Report Negative Earnings Next Week? What You Should Know

Peak potential revenue for both products is estimated in excess of $100 million Peak potential revenue for both products is estimated in excess of $100 million

Marrone Bio Submits Regulatory Packages for Nematicides/Insecticides in United States and Brazil

Marrone's (MBII) advancements strengthen its lead position as the supplier of choice for growers looking to meet the high demand for responsibly-grown food and fiber.

Marrone Bio (MBII) Herbicides Enter Late-Stage Development

Company Also Looks to Expand Footprint in South America with Regulatory Submission of Bionematicide Seed Treatment, MBI-206, in Brazil Company Also Looks to Expand Footprint in South America with Regulatory Submission of Bionematicide Seed Treatment, MBI-206, in Brazil

Marrone Bio Prepares to Submit Registration for Next-Generation Crop Protection Product in North America

Marrone (MBII) and Terramera are collaborating to bring technological and biological know-how to the market to enhance crop protection and create sustainable agricultural technologies.

Marrone (MBII) & Terramera Partner to Boost Crop Protection

Marrone Bio's (MBII) Q2 revenues were affected by severe drought in the western United States that led to reduced demand for insecticides and fungicides.

Marrone Bio (MBII) Q2 Earnings and Revenues Miss Estimates

Marrone Bio Innovations' (MBII) CEO Kevin Helash on Q2 2021 Results - Earnings Call Transcript

Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of -100.00% and -28.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Marrone Bio Innovations, Inc. (MBII) Reports Q2 Loss, Lags Revenue Estimates

Shares of Marrone Bio Innovations (NASDAQ:MBII) fell 4.8% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 0.00% year over year to ($0.02), which missed the estimate of ($0.01).

Marrone Bio Innovations: Q2 Earnings Insights

DAVIS, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the second quarter ended June 30, 2021. Key results include:

Marrone Bio Innovations, Inc. Reports Second-Quarter 2021 Financial Results

Marrone Bio Innovations, Inc. (MBII) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Bioceres Crop Solutions Corp

Marrone Bio Innovations Inc (NASDAQ:MBII) (FRA:0MB) and partner Rizobacter have announced that Rizonema, a biological seed treatment for nematodes and soil-dwelling insects, will be offered for use in row crops in Brazil, through an expanded distribution agreement.  In a statement, Marrone Bio said multiple regulatory trials in Brazil have proven the efficacy of Rizonema on key nematode species in soybeans and corn.

Marrone Bio and partner Rizobacter expand strategic alliance to supply Rizonema seed treatment in Brazil

Marrone's products are made from naturally-occurring substances like bacteria or plant extracts Biopesticides used in conjunction with chemical ones gives growers more control over pests The biopesticide industry is projected to more than double to $6.4 billion by 2023 What Marrone Bio does: Marrone Bio Innovations Inc (NASDAQ:MBII) is leading the charge toward more environmentally-conscious effective pest management for farmers with its unique line of biological pesticides. Its products are made from naturally occurring substances such as microbes, bacteria, plant extracts, fatty acids or pheromones, and it is currently the only publicly traded biopesticide company on the US market.

Marrone Bio leading the charge toward more environmentally-conscious effective pest management for farmers

Marrone Bio Innovations Inc (NASDAQ: MBII) has entered into a partnership with ATP Nutrition of Manitoba to distribute Stargus Biofungicide on Canadian broad-acre crops such as canola, dry beans, peas, soybeans, and sunflower.  The company said these products represent more than 30 million acres in Canada where the biocontrol market is estimated to be growing at a 12-15% compound annual growth rate.

Marrone Bio strikes partnership with ATP Nutrition to distribute Stargus Biofungicide on Canadian broad-acre crops

Agreement Marks Expansion into the Broad Acre Crops Market Agreement Marks Expansion into the Broad Acre Crops Market

Marrone Bio Innovations Partners with ATP Nutrition to Distribute Stargus® Biofungicide in Canada

Marrone Bio Innovations' (MBII) CEO Kevin Helash on Q1 2021 Results - Earnings Call Transcript

Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of 0.00% and -0.20%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Marrone Bio Innovations, Inc. (MBII) Reports Q1 Loss, Misses Revenue Estimates

Marrone Bio Innovations Inc (NASDAQ) reported its 11th consecutive growth quarter with revenues increasing 14% year-over-year to $11 million. The Davis, California-based group attributed the revenue growth to “further market penetration” for its biological crop protection products, particularly driven by its Venerate, Grandevo, and Regalia brands.

Marrone Bio sees 1Q revenue grow 14% on improved balance sheet amid strong biological crop protection sales

DAVIS, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) has provided its financial results for the first quarter ended March 31, 2021. Key results include:

News for Marrone Bio Innovations Stock (MBII)